By Catherine Shaffer, BioWorld Today Contributing Writer A research collaboration between Pfizer Inc. and Biovista Inc. will seek new indications for Pfizer drug candidates in development using a bioinformatics technology platform developed by Biovista. Terms of the agreement include identification of up to three new indications for each drug. Biovista will receive an undisclosed up-front … Read More
News
BioWorld: A Deep Dive into Pfizer’s Emerging Biotech Strategy
By Arlene Weintraub, BioWorld Insight On Nov. 9, the company formed a research collaboration with Biovista Inc…
Biovista Announces a Drug Repositioning Collaboration With Pfizer
CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ — Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista’s Clinical Outcome Search Space (COSS) technology. Under the terms … Read More
Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
CHARLOTTESVILLE, Virginia, July 13, 2010 /PRNewswire/ — Biovista announced today the appointment of Mr. Clifford H. Farrah, President and Chairman of The Beacon Group, to its Advisory Board. “We are very excited to have Cliff join our Advisory Board,” said Aris Persidis, President of Biovista. “Cliff brings a wealth of direct commercial development experience in … Read More
Biovista Featured in CHI’s InsightPharma Report on Drug Repositioning
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning. The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the … Read More